A placebo controlled study to assess the efficacy and safety of LOU064 in patients with inadequately controlled asthma

Phase 1

• Conditions: Inadequately controlled asthma; MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders; Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

• Registration Number: EUCTR2018-003609-24-PL
• Lead Sponsor: ovartis Pharma AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-07-03
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 154

Inclusion Criteria

•Male and female adult patients aged = 18 to = 70 years at screening
•Patients must weigh at least 40 kg to participate in the study, and must have a body mass index (BMI) <35 kg/m2. BMI = Body weight (kg) / [Height (m)]2 at screening
•Patients with a physician-diagnosed history of asthma (according to GINA (2018)) for a period of at least 6 months prior to screening.
•Patients who have been treated with:
•Medium or high dose ICS, or
•ICS plus long-acting beta agonist (LABA), or
•ICS plus leukotriene receptor antagonist (LTRA), or
•ICS plus long-acting beta agonist (LABA) and long lasting muscarinic antagonist (LAMA) for at least 1 month prior to screening and on the same doses of the above mentioned medications over at least 2 weeks prior to start of the run-in period.
•Post-bronchodilator reversibility of FEV1 = 12% and = 200 mL at screening. If reversibility is not demonstrated at screening, then two additional attempts are permitted (one at the run-in visit and the last one during the run in period between run in visit and baseline visit if needed).
•Spirometry with pre-bronchodilator FEV1 = 40% of predicted (at screening and baseline) and = 85% of predicted at the baseline visit.
•ACQ-5 score = 1.5 at baseline visit
•= 80% compliance with peak expiratory flow measurement and recording of symptoms in the eDiary during the run-in period.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 140
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 14

Exclusion Criteria

•Patients who have had an asthma exacerbation requiring systemic corticosteroids, hospitalization, or emergency room visit within 6 weeks prior to screening or during the screening period.
•Patients who have smoked or inhaled any substance other than asthma medications within the 6 month period prior to screening, or who have a smoking history of greater than 10 pack years (e.g. 10 pack years = 1 pack/day x 10 years or ½ pack/day x 20 years, etc.).
•History of life-threatening asthma event such as significant hypercarbia (pCO2 > 45 mmHg), endotracheal intubation, non-invasive positive pressure ventilation (NIPPV), respiratory arrest, or seizure as a result of asthma.
•Patients with chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, clinically significant bronchiectasis, sarcoidosis, interstitial lung disease, cystic fibrosis, Churg-Strauss syndrome, allergic broncho-pulmonary aspergillosis, or clinically significant chronic lung diseases related to a history of tuberculosis or asbestosis.
•At screening and/or run-in period, any severe, progressive or uncontrolled, acute or chronic, medical or psychiatric condition, or other factors such as abnormal vital signs, ECG or physical findings, or clinically relevant abnormal laboratory values, that in the judgment of the investigator may increase the risk associated with study participation/treatment or may interfere with interpretation of study results, and thus would make the patient inappropriate for entry into or continuing the study.
•Major surgery within 8 weeks prior to screening or surgery planned prior to end of study.
•History of live attenuated vaccine within 6 weeks prior to randomization or requirement to receive vaccinations at any time during the study.
•Hematology parameters at screening:
•Hemoglobin: < 10 g/dl
•Platelets: < 100 000/mm3
•White blood cells: < 3 000/mm3
•Neutrophils: < 1 500/mm3
•Significant bleeding risk or coagulation disorders.
•History of gastrointestinal bleeding, e.g. in association with use of Nonsteroidal Anti-Inflammatory Drug (NSAID).
•Requirement for anti-platelet or anticoagulant medication (e.g., warfarin, or clopidogrel or Novel Oral Anti-Coagulant - NOAC) other than acetylsalicylic acid (up to 100 mg/d).
•History or presence of thrombotic or thromboembolic event, or increased risk for thrombotic or thromborembolic event.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified